Skip to content
GinjerNews

BloombergHealth

Sellas Life Sciences Stock Triples After Cancer Vaccine Data

By Avalon Pernell

Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.

This story was published by Bloomberg. Read the full article on their site.

Read the full story at bloomberg.com(opens in a new tab)

More Health